The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry.
Open accessAbstract
OBJECTIVE: As psychopathology and social functioning can worsen with repeated psychotic episodes in schizophrenia, relapse prevention is critical. Because high nonadherence rates limit the efficacy of pharmacotherapy, the use of long-acting injectable (LAI) antipsychotics is considered an important treatment option. To date, many studies comparing LAIs and oral antipsychotics have been conducted; however, the results are mixed, and careful interpretation of the data is required. STUDY DESIGN AND SETTING: Selective review of existing literature regarding LAIs. We especially focused the discussion on the impact of the design of studies with different approaches comparing LAIs and oral antipsychotics in preventing relapse. RESULT: The results were diverse and were influenced by the design used, that is, randomized controlled trials (RCTs) showed LAIs and oral antipsychotics to have similar effects, whereas mirror-image and some large cohort studies showed LAIs to be superior to oral antipsychotics. CONCLUSION: Divergent results from studies using different methodologies create a dilemma for comparative effectiveness research, and LAI studies may serve as an example of a situation in which a conventional RCT is not the gold standard. Traditional RCTs generally increase adherence compared with clinical practice and, therefore, might not be well suited to detect differences between LAIs and oral medications, because any increase in adherence affects patients on oral medications more than those on LAIs and thus leads to an underestimation of any potential difference in effectiveness. A possible solution would be the implementation of a true effectiveness trial in which post-randomization involvement would be kept to a minimum to better reflect routine practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Although RCTs can provide the highest level of evidence, this design may selectively recruit participants who are more adherent to treatment than general patient populations.16”
From Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial (2020) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
The Expert Consensus Guideline Series
Velligan, D. I., Weiden, P. J., Sajatovic, M., Scott, J. L., Carpenter, D., Ross, R., & Docherty, J. P. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.7090su1cj · Cited by 692
Velligan, D. I., Weiden, P. J., Sajatovic, M., Scott, J. L., Carpenter, D., Ross, R., & Docherty, J. P. (2009) · PubMed · Cited by 625
Tiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10081224 · Cited by 619
Leucht, S., Hierl, S., Kissling, W., Dold, M., & Davis, J. M. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.096594 · Cited by 451 · cited 1×
“These effects are as dramatic as those of many other widely accepted treatments in general medicine [1].”
BackgroundLeucht, C., Heres, S., Kane, J. M., Kissling, W., Davis, J. M., & Leucht, S. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2010.11.020 · Cited by 424
Self-citationTiihonen, J., Wahlbeck, K., Lönnqvist, J. K., Klaukka, T., Ioannidis, J. P. A., Volavka, J., & Haukka, J. K. (2006) · BMJ · doi:10.1136/bmj.38881.382755.2f · Cited by 389
Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia
Rosenheck, R. A., Krystal, J. H., Lew, R., Barnett, P. G., Fiore, L. D., Valley, D., Thwin, S. S., Vertrees, J. E., & Liang, M. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1005987 · Cited by 213
Partial Compliance and Patient Consequences in Schizophrenia
Keith, S. J., & Kane, J. M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1105 · Cited by 201
Self-citationByerly, M., Fisher, R., Whatley, K., Holland, R., Varghese, F. P., Carmody, T. J., Magouirk, B., & Rush, A. J. (2005) · Psychiatry Research · doi:10.1016/j.psychres.2004.11.002 · Cited by 181
Cited by
Sorted by citations
What is the risk‐benefit ratio of long‐term antipsychotic treatment in people with schizophrenia?
Correll, C. U., Rubio, J. M., & Kane, J. M. (2018) · World Psychiatry · doi:10.1002/wps.20516 · Cited by 324
Self-citationMasuda, T., Misawa, F., Takase, M., Kane, J. M., & Correll, C. U. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1702 · Cited by 321
Self-citationThe role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal
Brissos, S., Veguilla, M. R., Taylor, D., & Balanzá-Martinez, V. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314540297 · Cited by 297
Marcus, S. C., Zummo, J., Pettit, A. R., Stoddard, J. J., & Doshi, J. A. (2015) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2015.21.9.754 · Cited by 251
Series: Pragmatic trials and real world evidence: Paper 1. Introduction
Zuidgeest, M. G. P., GOETZ, I. A., Groenwold, R. H. H., Irving, E. A., van Thiel, G. J. M. W., & Grobbee, D. E. (2017) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.12.023 · Cited by 232
Kane, J. M., Schooler, N. R., Marcy, P., Correll, C. U., Achtyes, E. D., Gibbons, R. D., & Robinson, D. G. (2020) · JAMA psychiatry · doi:10.1001/jamapsychiatry.2020.2076 · Cited by 208
Self-citationKaplan, G., Casoy, J., & Zummo, J. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s53795 · Cited by 201
Kishimoto, T., Hagi, K., Nitta, M., Leucht, S., Olfson, M., Kane, J. M., & Correll, C. U. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx090 · Cited by 186
Self-citationCorrell, C. U., Martin, A. L., Patel, C. A., Benson, C. J., Goulding, R., Sliwa, J. K., Joshi, K., Schiller, E., & Kim, E. (2022) · Schizophrenia · doi:10.1038/s41537-021-00192-x · Cited by 168
Self-citationEmerging Role of MicroRNAs as Liquid Biopsy Biomarkers in Gastrointestinal Cancers
Shigeyasu, K., Toden, S., Zumwalt, T. J., Okugawa, Y., & Goel, A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1676 · Cited by 151
Alphs, L. D., Benson, C. J., Cheshire-Kinney, K., Lindenmayer, J., Mao, L., Rodriguez, S. C., & Starr, H. L. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09584 · Cited by 137
Krogmann, A., Peters, L., von Hardenberg, L., Bödeker, K., Nöhles, V. B., & Correll, C. U. (2019) · CNS Spectrums · doi:10.1017/s109285291900124x · Cited by 120
Self-citationClinical benefits and impact of early use of long‐acting injectable antipsychotics for schizophrenia
Stevens, G. L., Dawson, G., & Zummo, J. (2016) · Early Intervention in Psychiatry · doi:10.1111/eip.12278 · Cited by 109
The Role of Clozapine in Treatment-Resistant Schizophrenia
Kane, J. M., & Correll, C. U. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2966 · Cited by 98
Self-citationTreatment of early episode in patients with schizophrenia: the role of long acting antipsychotics
Heres, S., Lambert, M., & Vauth, R. (2014) · European Psychiatry · doi:10.1016/s0924-9338(14)70001-x · Cited by 88
Determinants of adherence to treatment in first-episode psychosis: a comprehensive review
Leclerc, E., Noto, C., Bressan, R. A., & Brietzke, E. (2015) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2014-1539 · Cited by 78
Binder, M. D., Sermon, J., Geerts, P., Vansteelandt, K., Peuskens, J., & Detraux, J. (2015) · CNS Drugs · doi:10.1007/s40263-015-0269-4 · Cited by 81
Ostuzzi, G., Bighelli, I., So, R., Furukawa, T. A., & Barbui, C. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.11.010 · Cited by 80
Guinart, D., Misawa, F., Rubio, J. M., Pereira, J., de Filippis, R., Gastaldon, C., Kane, J. M., & Correll, C. U. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13359 · Cited by 61
Self-citationValue of schizophrenia treatment I: The patient journey
Mohr, P., Galderisi, S., Boyer, P., Wasserman, D., Arteel, P., Ieven, A., Kärkkäinen, H., Pereira, E., Guldemond, N., Winkler, P., et al. (2018) · European Psychiatry · doi:10.1016/j.eurpsy.2018.06.007 · Cited by 58
Mohr, P., Knytl, P., Voráčková, V., Bravermanová, A., & Melicher, T. (2017) · International journal of clinical practice · doi:10.1111/ijcp.12997 · Cited by 43
Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
Mathews, M., Gopal, S., Nuamah, I. F., Hargarter, L., Savitz, A. J., Kim, E., Tan, W., Soares, B. G., & Correll, C. U. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s197225 · Cited by 45
Self-citationSajatovic, M., Ross, R., Legacy, S. N., Correll, C. U., Kane, J. M., DiBiasi, F., Fitzgerald, H., & Byerly, M. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s167394 · Cited by 44
Self-citationFagiolini, A. M., Rocca, P., Giorgi, S. D., Spina, E., Amodeo, G., & Amore, M. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.11.044 · Cited by 44
Guinart, D., Taipale, H. T., Rubio, J. M., Tanskanen, A. J., Correll, C. U., Tiihonen, J., & Kane, J. M. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab062 · Cited by 48
Self-citationLorenzo, R. D., Ferri, P., Cameli, M., Rovesti, S., & Piemonte, C. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s189245 · Cited by 36
Neuroadaptations to antipsychotic drugs: Insights from pre-clinical and human post-mortem studies
Amato, D., Beasley, C. L., Hahn, M., & Vernon, A. C. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.10.004 · Cited by 41
Sajatovic, M., ROSS, R. W., Legacy, S. N., Byerly, M., Kane, J. M., DiBiasi, F., Fitzgerald, H. M., & Correll, C. U. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s167485 · Cited by 38
Self-citationLong-acting injectable antipsychotics treatment during COVID-19 pandemic – A new challenge
Ifteni, P. I., Dima, L., & Teodorescu, A. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.04.030 · Cited by 39
Suzuki, T. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1115479 · Cited by 40
Correll, C. U., Litman, R. E., Filts, Y., Llaudó, J., Naber, D., Torres, F., & Martínez, J. (2020) · Schizophrenia · doi:10.1038/s41537-020-00127-y · Cited by 38
Self-citationANDERSON, J. P., Icten, Z., Alas, V., Benson, C. J., & Joshi, K. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1507-8 · Cited by 37
Munday, J., Greene, M., Chang, E. Y., Hartry, A., Yan, T., & Broder, M. S. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1571295 · Cited by 36
Glutamatergic agents for schizophrenia: current evidence and perspectives
Zink, M., & Correll, C. U. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1040393 · Cited by 36
Self-citationBossie, C. A., Alphs, L. D., & Correll, C. U. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000082 · Cited by 33
Self-citationOlagunju, A. T., Clark, S. R., & Baune, B. T. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419837358 · Cited by 33
MacEwan, J. P., Kamat, S., Duffy, R. A., Seabury, S. A., Chou, J. W., Legacy, S. N., Hartry, A., Eramo, A., & Karson, C. N. (2016) · Psychiatric Services · doi:10.1176/appi.ps.201500455 · Cited by 32
Verdoux, H., Pambrun, É., Tournier, M., Bezin, J., & Pariente, A. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12722 · Cited by 31
Schöttle, D., Janetzky, W., Luedecke, D., Beck, E., Correll, C. U., & Wiedemann, K. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1946-x · Cited by 29
Self-citationVita, G., Tavella, A., Ostuzzi, G., Tedeschi, F., Prisco, M. D., Segarra, R., Solmi, M., Barbui, C., & Correll, C. U. (2024) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253241257062 · Cited by 31
Self-citationDecuypere, F., Sermon, J., Geerts, P., Denee, T. R., de Vos, C. D., Malfait, B., Lamotte, M., & Mulder, C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179049 · Cited by 28
Chestnykh, D., Amato, D., Kornhuber, J., & Müller, C. P. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113144 · Cited by 33
Correll, C. U., Sliwa, J. K., Najarian, D. M., & Saklad, S. R. (2019) · CNS Spectrums · doi:10.1017/s1092852918001098 · Cited by 27
Self-citationWeiser, M., Davis, J. M., Brown, C. H., Slade, E. P., Fang, L., Medoff, D. R., Buchanan, R. W., Levi, L. W., Davidson, M., & Kreyenbuhl, J. A. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20111657 · Cited by 24
Correll, C. U., Benson, C. J., Émond, B., Patel, C. A., Lafeuille, M., Lin, D., Morrison, L., Ghelerter, I., Lefèbvre, P., & Mavros, P. (2023) · Schizophrenia · doi:10.1038/s41537-023-00334-3 · Cited by 25
Self-citationPeters, L., Krogmann, A., von Hardenberg, L., Bödeker, K., Nöhles, V. B., & Correll, C. U. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1114-0 · Cited by 25
Self-citationThoma, R., Chaze, C., Lewine, J., Calhoun, V., Clark, V., Bustillo, J., Houck, J., Ford, J., Bigelow, R., Wilhelmi, C., et al. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2016.00039 · Cited by 26
Medrano, S., Abdel‐Baki, A., Stip, É., & Potvin, S. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4577 · Cited by 24
Lafeuille, M., Frois, C., Cloutier, M., Duh, M. S., Lefèbvre, P., Pesa, J. A., Clancy, Z., Fastenau, J. M., & Durkin, M. (2016) · Europe PMC (PubMed Central) · Cited by 22
Histoire des traitements antipsychotiques à action prolongée dans la schizophrénie
Crocq, M. A. (2015) · L Encéphale · doi:10.1016/j.encep.2014.12.002 · Cited by 23
Riboldi, I., Cavaleri, D., Capogrosso, C. A., Crocamo, C., Bartoli, F., & Carrà, G. (2022) · Psychology Research and Behavior Management · doi:10.2147/prbm.s371991 · Cited by 22
Current and Emergent Treatments for Symptoms and Neurocognitive Impairment in Schizophrenia
Javitt, D. C. (2014) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-014-0010-9 · Cited by 23
Girardi, P., CASALE, A. D., Rapinesi, C., Kotzalidis, G. D., Splendori, F., Verzura, C., Trovini, G., Sorice, S., Carrus, D., Mancinelli, I., et al. (2018) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2658 · Cited by 21
Schneeweiß, S., Seeger, J. D., Jackson, J. W., & Smith, S. R. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.05.012 · Cited by 20
Naber, D., Baker, R. A., Eramo, A., Forray, C., Hansen, K., Sapin, C., Peters-Strickland, T. S., Nylander, A., Hertel, P., Schmidt, S. N., et al. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.04.013 · Cited by 21
Poloni, N., Ielmini, M., Caselli, I., Lucca, G., Gasparini, A., Gasparini, A., Lorenzoli, G., & Callegari, C. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4590 · Cited by 20
Abdel‐Baki, A., Medrano, S., Maranda, C., Ladouceur, M., Tahir, M. R., Stip, É., & Potvin, S. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000310 · Cited by 20
Schöttle, D., Janetzky, W., Luedecke, D., Beck, E., Correll, C. U., & Wiedemann, K. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02488-1 · Cited by 19
Self-citationMiura, G., Misawa, F., Kawade, Y., Fujii, Y., Mimura, M., & Kishimoto, T. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001082 · Cited by 17
Self-citationPae, C., Han, C., Bahk, W., Lee, S.-J., Patkar, A. A., & Masand, P. S. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.3.434 · Cited by 18
Mustafa, F. A. (2017) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.12699 · Cited by 17
Feng, Y., Si, T., Zhang, K.-R., Tang, J., Fang, M., Li, K., & Zhuo, J. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s81760 · Cited by 16
Emsley, R. A., Parellada, E., Bioque, M., Herrera, B., Hernando, T., & Dorado, M. G. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000195 · Cited by 15
Bartoli, F., Cavaleri, D., Callovini, T., Riboldi, I., Crocamo, C., D’Agostino, A., Martinotti, G., Bertolini, F., Ostuzzi, G., Barbui, C., et al. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114405 · Cited by 15
Pietrini, F., Spadafora, M., Tatini, L., Talamba, G. A., Andrisano, C., Boncompagni, G., Manetti, M., Ricca, V., & Ballerini, A. (2016) · European Psychiatry · doi:10.1016/j.eurpsy.2016.05.008 · Cited by 15
Bozzatello, P., Bellino, S., Mancini, I., Sandei, L., Zanalda, E., & Rocca, P. (2018) · Clinical Drug Investigation · doi:10.1007/s40261-018-0734-1 · Cited by 15
Integrated treatment of schizophrenia
Altamura, A. C., Fagiolini, A. M., Galderisi, S., Rocca, P., & Rossi, A. (2015) · Use Siena air (University of Siena) · Cited by 14
Auxilia, A. M., Buoli, M., Caldiroli, A., Carnevali, G. S., Tringali, A. G. M., Nava, R., Clerici, M., & Capuzzi, E. (2023) · Biomedicines · doi:10.3390/biomedicines11020314 · Cited by 14
Treatment resistance and other complicating factors in the management of schizophrenia
Strassnig, M., & Harvey, P. D. (2014) · CNS Spectrums · doi:10.1017/s1092852914000571 · Cited by 14
Guidelines for the use of second-generation long-acting antipsychotics
Jarema, M., Wichniak, A., Dudek, D., Samochowiec, J., Bieńkowski, P., & RYBAKOWSKI, J. K. (2015) · Psychiatria Polska · doi:10.12740/pp/39370 · Cited by 14
The polygenic basis of relapse after a first episode of schizophrenia.
Segura, À., Prohens, L., Gassó, P., Rodríguez, N., García-Rizo, C., Moreno-Izco, L., Andreu-Bernabeu, Á., Zorrilla, I., Mané, A., Rodríguez-Jiménez, R., et al. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.06.003 · Cited by 14
Chen, W. J., Liu, C., Liu, C.-C., Kuo, P., Chan, H., Lin, Y., Chung, Y.-C. E., & Chen, W. J. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.17006 · Cited by 13
The safety, efficacy and tolerability of Abilify Maintena for the treatment of schizophrenia
Kahn, R. S., & Giannopoulou, A. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1070670 · Cited by 13
Morrato, E. H., Parks, J., Campagna, E. J., Muser, E., Thomas, D. S. K., Fang, H., & Doshi, D. (2014) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.14.50 · Cited by 13
Oya, K., Kishi, T., & Iwata, N. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s91397 · Cited by 13
Litman, R. E., Naber, D., Anta, L., Martínez, J., Filts, Y., & Correll, C. U. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s392351 · Cited by 14
Self-citationCritical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia
Carpiniello, B., & Pinna, F. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s86301 · Cited by 12
Correll, C. U., Brieden, A., & Janetzky, W. (2023) · Schizophrenia · doi:10.1038/s41537-023-00405-5 · Cited by 14
Self-citationPatel, R., Brinn, A., Irving, J., Chaturvedi, J., Gudiseva, S., Correll, C. U., Fusar‐Poli, P., & McGuire, P. K. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231211575 · Cited by 11
Self-citationCompulsory community treatment: beyond randomised controlled trials
Mustafa, F. A. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30420-6 · Cited by 11
Vgontzas, A. N., Paschalidou, A., Simos, P. G., Anastasaki, M., Zografaki, A., Volikos, E., Koutra, K., & Basta, M. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115676 · Cited by 10
Correll, C. U. (2025) · CNS Spectrums · doi:10.1017/s1092852925100503 · Cited by 11
Self-citationTreatment Duration With Long-Acting Injectable Antipsychotics After In-hospital Initiation
Rittmannsberger, H., Rosenleitner, J., Malsiner‐Walli, G., Werl, R., Rittmannsberger, B., & Yazdi, K. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000672 · Cited by 10
Jackson, J. W., Fulchino, L. A., Rogers, J. R., Mogun, H., Polinski, J. M., Henderson, D., Schneeweiss, S., & Fischer, M. (2018) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4354 · Cited by 11
Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?
Maestri, T. J., Mican, L. M., Rozea, H., & Barner, J. C. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4571 · Cited by 10
Fusar‐Poli, P., Pillinger, T., McCutcheon, R. A., Rangaswamy, T., Asmal, L., Singh, S. P., Oliver, D., Stefanelli, R., Crossley, N. A., Gadelha, A., et al. (2026) · World Psychiatry · doi:10.1002/wps.70066 · Cited by 19
Self-citationMontemagni, C., Favero, E. D., Cocuzza, E., Vischia, F., & Rocca, P. (2022) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253221122526 · Cited by 10
Adamus, C., Zürcher, S. J., & Richter, D. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04133-5 · Cited by 8
Yoshimatsu, K., Elser, A., Thomas, M., Dilley, J., Barnes, D. E., Ballinger, A. L., Wozniak, S., & Mangurian, C. V. (2019) · Community Mental Health Journal · doi:10.1007/s10597-019-00412-w · Cited by 8
Levitan, B. S., Markowitz, M., Turkoz, I., Fu, D., Gopal, S., & Alphs, L. D. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000141 · Cited by 8
Efficacy of LAI in first episode psychosis: an observational study--clinical reports.
Cervone, A., D’Onghia, A., Ferrara, M., & Massaro, C. R. M. (2015) · PubMed · Cited by 7
Switching away from pipotiazine palmitate: a naturalistic study
Mustafa, F. A. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316672575 · Cited by 7
Impact of long-acting injectable antipsychotics in early psychosis: An umbrella review
Etienne, M., & Verdoux, H. (2025) · Schizophrenia Research · doi:10.1016/j.schres.2025.03.002 · Cited by 6
Bardi, F., Moccia, L., Kotzalidis, G. D., Boggio, G., Brugnami, A., Sfratta, G., Janiri, D., Sani, G., & Simonetti, A. (2025) · Healthcare · doi:10.3390/healthcare13141709 · Cited by 6
Cameron, C. G., Zummo, J., Desai, D. N., Drake, C., Hutton, B., Kotb, A., & Weiden, P. J. (2017) · Value in Health · doi:10.1016/j.jval.2017.03.010 · Cited by 6
Meyer, A., Truman, K. A., Totlani, J., William, C., Brown, H., Shah, S. R., Hirsch, D., Salem, M., Chang, T., Abdelsalam, R., et al. (2024) · The International Journal of Psychiatry in Medicine · doi:10.1177/00912174241310091 · Cited by 5
RetractedCarmassi, C., Milani, F., Bertelloni, C. A., Massimetti, E., Cerù, A., & Dell’Osso, L. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13787 · Cited by 5
Zhang, Q., Zhong, F., Wu, M., & Zhang, X. (2014) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-014-1299-8 · Cited by 5
Brasso, C., Beoni, A. M., Colli, G., Mariani, G. N., & Rocca, P. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251367591 · Cited by 4
Cirnigliaro, G., Battini, V., Cafaro, R., Mosini, G., Vanzetto, S., Prodi, T., Macellaro, M., Leuzzi, R., Conti, D., Carnovale, C., et al. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2263650 · Cited by 4
Metadata
- Authors
- Kane, J. M., Kishimoto, T., & Correll, C. U.
- Affiliations
- Albert Einstein College of Medicine (US)
- Northwell Health (US)
- Corresponding author
- Kane, John M.
- Venue
- Journal of Clinical Epidemiology
- Publisher
- Elsevier BV
- Published
- 2013-08
- Volume
- 66
- Issue
- 8
- Pages
- S37-S41
- ISSN
- 0895-4356 (ISSN-L)
- PMC
- PMC3742035
- OpenAlex
- W2012479321
- Semantic Scholar
- 953666f6c829e3913f6fe5f7aced501c8c2e2dc1
- Cited by
- 131
- References
- 20
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 5 · 2023: 10 · 2022: 6 · 2021: 8 · 2020: 6 · 2019: 14 · 2018: 12 · 2017: 15 · 2016: 14 · 2015: 17 · 2014: 8 · 2013: 2
- FWCI
- 9.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Clinical Epidemiology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (P30MH074543, P30MH060575, P30MH090590)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Keywords
- long-acting injectable antipsychotics, oral antipsychotics, relapse prevention, schizophrenia, medication adherence, randomized controlled trials, mirror-image study, cohort studies, comparative effectiveness research
- MeSH terms
- Assessment of Medication Adherence, Delayed-Action Preparations, Humans, Injections, Intramuscular, Psychiatry, Research Design, Schizophrenia, Antipsychotic Agents, Cohort Studies, Bias, Randomized Controlled Trials as Topic, Treatment Outcome, Drug Monitoring, Patient Selection, Medication Adherence, Secondary Prevention, Comparative Effectiveness Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
